Thursday, 28 August 2014
Post-Authorization Activity Table (PAAT) for ERIVEDGE
The PAAT describes post-authorization activity for Erivedge, a product which contains the medicinal ingredient vismodegib. Based on Health Canada's review, the benefit/risk profile of Erivedge is favourable for the treatment of adult patients with histologically confirmed metastatic basal cell carcinoma or locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy. Read more here.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment